Dry Powder Inhaler Market Report 2026

Dry Powder Inhaler Market Overview

• Dry Powder Inhaler market size has reached to $22.18 billion in 2025 • Expected to grow to $28.16 billion in 2030 at a compound annual growth rate (CAGR) of 4.9% • Growth Driver: Rising Prevalence Of Respiratory Diseases Fuels Growth In The Dry Powder Inhaler Market • Market Trend: Innovative Products And Market Expansion Strategies In The Dry Powder Inhaler (DPI) Market • North America was the largest region in 2025.

What Is Covered Under Dry Powder Inhaler Market?

A dry powder inhaler (DPI) refers to a medical device used for delivering medication directly to the lungs in the form of dry powder. It is designed to treat respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). It is essential for the user to inhale rapidly and deeply to enable the medication to reach the lungs to utilize a DPI effectively. The main types of products in dry powder inhalers are single-dose inhalers and multi-dose inhalers. A single-dose inhaler refers to a dry powder inhalation device that administers medication directly to the lungs. It performs various functions, such as manually operated inhaler devices and digitally operated inhaler devices and used in a variety of applications such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others. It also includes a variety of end-users, including hospitals and clinics, homecare settings, ambulatory surgical centers and others.

What Is The Dry Powder Inhaler Market Growth Forecast?

The dry powder inhaler market size is expected to see steady growth in the next few years. It will grow to $28.16 billion in 2030 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to increasing integration of smart inhaler technologies, rising focus on personalized respiratory care, expansion of remote patient monitoring, growing demand for environmentally friendly inhalers, increasing adoption of digital health ecosystems. Major trends in the forecast period include increasing adoption of digitally operated inhalers, rising demand for patient-adherence monitoring, growing focus on portable and user-friendly designs, expansion of multi-dose inhaler platforms, enhanced focus on dose accuracy.

Global Dry Powder Inhaler Market Segmentation

1) By Product: Single-Dose Inhalers, Multi-Dose Inhalers 2) By Function: Manually Operated Inhaler Devices, Digitally Operated Inhaler Devices 3) By Application: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Other Applications 4) By End User: Hospitals And Clinics, Homecare Settings, Ambulatory Surgical Centers, Other End Users Subsegments: 1) By Single-Dose Inhalers: Capsule-Based Inhalers, Diskus-Based Inhalers 2) By Multi-Dose Inhalers: Blister-Based Inhalers, Rotahaler-Based Inhalers

What Is The Driver Of The Dry Powder Inhaler Market?

The growing prevalence of respiratory diseases is expected to propel the growth of the dry powder inhaler market going forward. Respiratory diseases refer to respiratory disorders or lung diseases, encompassing a broad category of medical conditions affecting the respiratory system. Dry powder inhalers are essential in treating respiratory conditions such as asthma, COPD, and cystic fibrosis as they deliver medicine directly to the lungs, where it is most effective. It is a promising alternative to traditional drug delivery methods for respiratory diseases. For instance, in December 2023, according to a research study published by JAMA Network Open, a medical journal by the American Medical Association, the global burden of chronic obstructive pulmonary disease (COPD) projected that the cases worldwide could reach nearly 600 million by 2050, marking a 23% increase in prevalence. Therefore, the growing prevalence of respiratory diseases will drive the growth of the dry powder inhaler industry.

Key Players In The Global Dry Powder Inhaler Market

Major companies operating in the dry powder inhaler market are Novartis AG, AstraZeneca plc., GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, Viatris (Mylan N.V), Otsuka Pharmaceutical Co. Ltd, Catalent Inc., Aptar Group Inc., Chiesi Farmaceutici S.p.A., Recipharm AB, Cipla Limited, Lupin Limited, Orion Corporation, Hovione, MannKind Corporation, Presspart Manufacturing Ltd, Teva Pharmaceutical Industries Limited, Pharmaxis Ltd., Iconovo AB, SRS Pharmaceuticals Pvt. Ltd.

Global Dry Powder Inhaler Market Trends and Insights

Major companies operating in the dry powder inhaler market are developing innovative products with muscarinic antagonist for treating chronic obstructive pulmonary disease (COPD) and expanding their product portfolio. A muscarinic antagonist is a drug that inhibits the muscarinic acetylcholine receptor. It controls and treats various illnesses, such as COPD and organophosphate poisoning. For instance, in March 2024, Berry Global, a US-based company known for developing and manufacturing a wide range of flexible packaging solutions, unveiled its new dry powder inhaler at Pharmapack, marking a strategic expansion into advanced drug-delivery technologies. The device is engineered to improve the efficiency and consistency of drug delivery for respiratory conditions, particularly COPD and asthma, where accurate dosing and ease of use are critical. Its customizable design allows pharmaceutical companies to tailor the inhaler to specific formulation needs, offering greater flexibility in product development. By combining patient-centric functionality with adaptable features, Berry Global aims to support innovation in the respiratory therapeutics space while strengthening its role as a partner for pharmaceutical manufacturers.

What Are Latest Mergers And Acquisitions In The Dry Powder Inhaler Market?

In August 2024, Aptar Pharma, a US-based expert in drug delivery, acquired the Orbital Dry Powder Inhaler for an undisclosed amount. This acquisition enhances Aptar's capabilities in respiratory drug delivery, particularly for treating conditions like asthma and chronic obstructive pulmonary disease (COPD). The Orbital Dry Powder Inhaler is recognized for its innovative design aimed at improving medication delivery. This move aligns with Aptar Pharma's strategy to broaden its product offerings and solidify its presence in the respiratory treatment market. The Orbital DPI operates within the pharmaceutical and medical device sectors in India.

Regional Outlook

North America was the largest region in the dry powder inhaler market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Dry Powder Inhaler Market?

The dry powder inhaler market consists of sales of dry powder forms, spiriva handihalers, breath-activated inhalers, rotahalers, diskus devices, and twisthaler inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.